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Summary  
 
Objective. Although somatoform disorders are assumed to be chronic clinical conditions, 
epidemiological knowledge on their natural course based on representative samples is not available. 
Method. Data come from a prospective epidemiologic study of adolescents and young adults in 
Munich, Germany. Respondents’ diagnoses (N = 2548) at baseline and follow-up on average 42 
months later are considered. The follow-up incidence, stability as well as selected baseline risk factors 
(sociodemographics, psychopathology, trauma exposure) for the incidence and stability of somatoform 
disorders and syndromes are prospectively examined. Diagnostic information was assessed by using 
the standardized Munich-Composite International Diagnostic Interview (M-CIDI). Results. Over the 
follow-up period, incidence rate for any of the covered somatoform diagnoses was 25.7%. Stability for 
the overall group of any somatoform disorder/syndrome was 48%. Female gender, lower social class, 
the experience of any substance use, anxiety and affective disorder as well as the experience of 
traumatic sexual and physical threat events predicted new onsets of somatoform conditions, while 
stability was predicted by being female, prior existing substance use, affective and eating disorders as 
well as the experience of a serious accident. Conclusions. At least for a substantial proportion of 
individuals, the overall picture of somatization seems to be relatively stable, but with fluctuation in the 
symptom picture over time. Being female, the experience of substance use as well as anxiety disorder 
seem to constitute risk factors for the onset of new somatoform conditions as well as for a stable 
course over time.     
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Introduction  
 
The key features of somatoform disorders as defined by latest edition of the American 
Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; 
[1]) are physical symptoms that are not fully explainable by a medical condition or by the 
effects of any substance or any other mental disorder. In the DSM-IV, subjects with 
presentations of medically unexplained symptoms are covered by the diagnostic group of 
somatoform disorders, which include somatization disorder as the prototype of somatoform 
disorders, hypochondriasis, pain disorder, conversion disorder as well as body dysmorphic 
disorder. Previous epidemiological studies on adults as well as on younger age groups have 
consistently shown that the prevalence rates for the full-blown somatoform disorders seem to 
be rather low (range: 0–2%; see [5,9,10,12,20,21, 26,32,34,35]). Less restricted defined forms 
of somatization, subsumed in the DSM-IV under the rest category of “undifferentiated 
somatoform disorder” have been found to be much more common. An example is the 
abridged form of somatization labeled Somatic Symptom Index (SSI4,6) introduced by 
Escobar et al. [8], defined as four symptoms in males and six in females, for which lifetime 
rates between 3% in adolescents and young adults [21] and 4.4–20% in adults [6,8,27] have 
been reported. Although these previous epidemiological studies have presented basic 
knowledge on the prevalence of somatoform disorders in the population, epidemiological data 
on the natural course of somatoform disorders in terms of incidence and stability as well as on 
factors associated with the natural course is sparse. This is remarkable, as assumptions about 
the natural course (i.e., chronicity) are even reflected in the current diagnostic criteria. For 
example, DSM-IV criteria emphasize the stability and chronicity of somatization disorder by 
defining this condition as a history of many physical complaints that begin before age 30 
years and persist over a period of several years. As far as we are aware, there are only three 
studies in the literature that examined incidence and stability of somatoform disorders. The 
World Health Organization’s Psychological Problems in General Health Care project 
examined incidence and stability of somatization in terms of the abridged SSI4,6 as well as 
somatoform symptoms prospectively over 12 months in primary care attenders [11]. Using the 
Composite International Diagnostic Interview (CIDI) as diagnostic instrument, researchers 
found that somatization according to SSI4,6 was persistent over a 12-month period in 46% of 
the patients. For specific symptoms, persistence ranged from 52% (joint pains) to a low of 0% 
(amnesia). The 12-month incidence rate of the SSI4,6 was found to be 7% in this clinical 
sample. As far as we are aware, this study is the only one in the literature that evaluated 
prospectively factors that are associated with stability and incidence of somatoform episodes 
over time. What they found was, that stability as well as incidence were predicted by self-
rated poor overall health and by impaired work role. Incidence of new somatoform episodes 
was additionally predicted by depression at baseline. The second study evaluated 
prospectively the 4- to 5-year course of DSM-III-R hypochondriasis. Medical outpatients 
meeting DSM criteria for hypochondriasis were followed over a period of about 5 years [3]. 
Investigators found that hypochondriasis seems to be quite stable: 64% of the patients meeting 
diagnostic criteria at first assessment still met criteria 5 years later. The third study applied 
DSM-III criteria to inpatient and outpatient medical records and contacted 98 patients who 
met criteria for DSM-III conversion and somatization disorder about 4 years later [15]. A total 
of 76.3% of the former cases with somatization disorder and 68.8% of the cases with 
hypochondriasis again fulfilled diagnostic criteria after this 4-year follow-up period. Thus, for 
clinical samples, these three studies support the widely accepted view of somatoform 
disorders as chronic and persistent clinical conditions. However, clinical samples may be 
biased by self-selection factors that may influence the generalizability of the findings. As far 
as we are aware, virtually no studies using a non-clinical sample have investigated the natural 
course in terms of incidence, stability and factors related to incidence and stability of a broad 
range of somatoform disorders by using a prospective-longitudinal design. By using such an 
approach, this paper aims to study (a) the incidence and stability of somatoform disorders and 
syndromes, as well as (b) baseline sociodemographic factors, psychopathology and traumatic 
events that are associated with the incidence and stability of these clinical conditions in a 
representative population sample of 3021 adolescents and young adults. These subjects were 
aged 14–24 at the outset of the study and have been followed prospectively over a period of 
about 4 years.  
 
Materials and Methods  
 
Overall design  
 
The data presented come from the Early Developmental Stages of Psychopathology Study 
(EDSP), a prospective-longitudinal survey designed to explore the prevalence and incidence, 
familial and other risk factors, comorbidity and course of mental disorders in a representative 
population sample of originally 3021 subjects aged 14–24 at baseline. The study consists of a 
baseline survey, two follow-up surveys, and a family history component. Detailed 
descriptions of the EDSP-design and field procedures are reported elsewhere [22,39].  
 
Sample and assessments  
 
The sample was drawn from the 1994 government registries of residents in Munich, Germany, 
expected to be 14–24 years of age at the time of the baseline interview in 1995. As the study 
was designed with special interest in early developmental stages of psychopathology, 14–15-
year-olds were sampled at twice the probability of 16–21-year-olds, and 22–24-year-olds 
were sampled at half this probability. At baseline (T0), a total of 3021 interviews were 
completed, resulting in a response rate of 71%. The two follow-up assessments were 
completed after the initial baseline investigation, covering an overall period of 3–4 years 
(depending on the timing of the follow-up interviews, which were conducted after intervals of 
approximately 18 months). The first follow-up study (T1) was conducted on average 19.7 
months (range = 15–25.6 months) after the baseline study with a response rate of 88%. Only 
the at baseline younger cohort (14–17 year-olds) were included in this wave. The second 
follow-up (T2), in which all baseline respondents were included again, was conducted in 
1998/99 an average of 42 months (range = 34–50 months) after baseline with a response rate 
of 84% (N = 2548). Sociodemographic characteristics of the baseline (T0) and entire follow-
up (T0–T2) sample have been published [22,31]. Briefly, at baseline, most of the respondents 
were attending school (89%) and living with their parents (97.8%). About 10% were in job 
training. The majority was classified as belonging to the middle class (61.4%). Noteworthy 
changes in sociodemographic characteristics from baseline to second follow-up were found 
for school (follow-up: 42% attended school) and employment status (follow-up: 24% were in 
job training program and 12% were employed).  
 
Diagnostic assessment  
 
Diagnostic assessments in the baseline and the two follow-up investigations of the 
respondents were based on the computer-assisted version of the Munich- Composite 
International Diagnostic Interview (M-CIDI) that allows for the assessment of symptoms, 
syndromes and diagnoses of 48 mental disorders according to the DSM-IV along with 
information about onset, duration, severity and psychosocial impairment (M-CIDI; [40]). 
Diagnostic findings are obtained by using the M-CIDI/DSM-IV algorithms. For a detailed 
discussion of the M-CIDI, see Wittchen et al. [36] and also Lachner et al. [19]. At baseline, 
the lifetime version of the M-CIDI was used. At each follow-up, the M-CIDI interval-version 
was applied. In all assessments the M-CIDI was supplemented by a separate respondent’s 
booklet that included several scales and questionnaires for assessing psychological constructs 
that are relevant to our study. A detailed overview and characterization of the constructs and 
assessment scales used has been presented elsewhere [13,22,38]. Reliability and validity 
findings of the M-CIDI [19,25,36] along with descriptions of the M-CIDI format and coding 
conventions have been reported in detail elsewhere. For the main diagnostic category “any 
somatoform disorder” the one-week test-retest reliability, investigated in a general population 
sample of 60 adolescents and young adults [36] aged 14–24 years, was acceptable (κ = 0.62). 
The validity—obtained by comparing M-CIDI-diagnoses of 68 randomly chosen patients to 
clinical diagnoses made by independent treating full licensed psychiatrists—was also 
sufficiently high (κ = 0.50). The sensitivity was 93.8%, while the specificity was 71.2% [25].  
 
Detailed descriptions of the training procedures, and fieldwork have been reported elsewhere 
[22,39]. Briefly, the highly experienced survey staff consisted of 57 clinical interviewers, 
most of whom were clinical psychologists. At baseline, 25 full-time professional health 
research interviewers were additionally included. Most of the interviewers had extensive 
experience in diagnostic interviewing including the CIDI and in the developmental work of 
the M-CIDI. All interviewers received two full weeks of training. In the fieldwork, most 
interviews were conducted in the home of the probands. To minimize errors and missing 
values, all interviewers were closely supervised by especially trained and clinically 
experienced M-CIDI editors. To reduce errors in the classification of symptoms as 
“somatoform”, the editors reviewed case-by-case the responses to somatoform symptoms for 
which verbatim quotes were available. This editing was intended to judge whether or not the 
respondent’s explanations as well as the interviewer’s classification of the symptoms were 
plausible.  
 
Assessment of somatoform disorders  
 
The M-CIDI section of somatoform disorders along with its coding conventions has already 
been fully described in a previous publication [21]. This section starts with a checklist of 46 
symptoms (according to DSM-IV or ICD-10), presented to obtain a fairly comprehensive 
account about all potential somatoform symptoms listed in DSM-IV and ICD-10 that the 
respondents might have had in their lifetimes. Each affirmed symptom is then explored with a 
series of probe questions that investigate whether a symptom is clinically significant and 
whether it can be entirely explained by a medical condition or the use of any substance 
(medication, drug or alcohol). Clinical significance is indicated either by seeking help from a 
medical doctor or other mental health professional, repeated intake of medication, or 
significant distress and interference with daily life because of the symptom. Only clinically 
significant symptoms are probed to determine whether they are fully explainable by a medical 
condition or the intake of any substance. The interviewer is directed to record and classify in a 
standardized way the subject’s response as: (1) the symptom has always been the result of a 
physical disease, condition or injury; (2) the symptom has always been due to the intake of 
any substance; or (3) the symptom is not fully explainable by a medical explanation. A 
symptom is classified as not fully explainable when the subject confirms that the symptom 
has neither been always the result of a somatic disease or injury nor has always been caused 
by the intake of any substances. Consistent with DSM-IV-stipulation, only the latter 
symptoms are counted towards a diagnosis of somatoform disorder or syndrome. Further, 
each somatoform symptom is probed for age of first onset, whereas age of last occurrence is 
only probed if the diagnostic threshold for the respective diagnosis is reached. The M-CIDI 
incorporates DSM-IV diagnostic algorithms for somatization disorder, pain disorder, 
conversion disorder and hypochondriasis. Additionally, selected symptom coverage allows for 
an evaluation of dissociative disorder not otherwise specified (NOS), whenever a subject 
reports clinically significant dissociative symptoms. Further, the M-CIDI offers algorithms for 
two sub-threshold variations that do not meet the threshold for any specific DSM-IV 
somatoform disorder: (1) the abridged somatization definition SSI4,6 according to Escobar et 
al. [8], defined as four symptoms in males and six in females, and (2) the “undifferentiated 
somatoform/ dissociative syndrome (USDS)”. The latter is assigned when the subject does not 
meet criteria for any other somatoform condition, but reports at least one clinically significant 
symptom with a minimum duration of 6 months and at least significant impairment during 
this period. Both of these conditions on the subthreshold diagnostic status are called 
“somatoform syndromes” in this report. Throughout the paper, unless otherwise stated, the 
DSM-IV diagnostic hierarchy rules were applied. Thus, for example, respondents who met 
criteria for somatization disorder or SSI4,6 were not assigned any other somatoform 
diagnosis, and USDS was only diagnosed when no specific somatoform disorder was present. 
Conversion disorder and dissociative disorder NOS were not defined as mutually exclusive.  
 
Assessment of baseline factors  
 
Besides the demographic variables age, gender, level of education and social class, the 
following factors were evaluated as baseline risk factors for the incidence and stability of 
somatoform disorders/syndromes: (a) prior history of mental disorders and (b) trauma 
exposure.  
 
Prior history of mental disorders. The history of prior mental disorders included the lifetime 
history of the following  
 
(1) any substance use disorders: alcohol abuse/ dependence, nicotine dependence, illicit drug 
abuse/ dependence;  
(2) any affective disorder: bipolar disorders, major depression, dysthymia;  
(3) any anxiety disorder: generalized anxiety disorder, panic disorder, agoraphobia w/o panic 
disorder, social phobia, specific phobia, obsessive compulsive disorder and posttraumatic 
stress disorder;  
(4) any eating disorder: anorexia nervosa, atypical anorexia nervosa, bulimia nervosa and 
atypical bulimia nervosa.  
 
Trauma exposure  
 
The respondent baseline interview included the structured trauma exposure checklist of the 
post-traumatic stress disorder module of the M-CIDI [23]. This module covers traumatic 
experiences outside the range of normal human experience as defined in DSM-IV as for 
triggers of post-traumatic stress disorder. The specific particular childhood traumas evaluated 
in this paper include physical attacks, rape or sexual abuse, and life-threatening accidents. All 
other traumas (being kidnapped, natural catastrophe, witness, and other trauma) were grouped 
into the category “other trauma”.   
 
Statistical analysis  
 
Analyses are based on the N = 2548 respondents who completed the whole study period (T0–
T2). For the younger cohort, the 14–17-year-olds at baseline (T0), the follow-up status is 
assessed from the aggregation of information obtained from the first (T0–T1) and second 
(T1–T2) follow-up interviews. For the older cohort, i.e., the respondents aged >17 at baseline, 
the follow-up status is assessed from the T2 questions, which refer to the time between T0 and 
T2.  
 
The data were adjusted by age, sex and geographic location to match the distribution of the 
sampling frame. A more detailed description of the EDSP weighting procedure is presented 
elsewhere [39]. The Stata Software package [30] was used to compute robust confidence 
intervals required when basing analyses on weighted samples [28].  
 
Logistic regressions with odds ratios (ORs) were used to describe associations between 
baseline factors and incidence and stability of somatoform disorders/ syndromes recognizing 
as confounding variables respondent’s age and gender. In order to assess differences in 
associations with baseline risk factors and incidence and stability of somatoform disorders 
and syndromes between males and females as well as between the younger and the older 
cohort, the interactions with these two variables were additionally tested.  
 
Results  
 
Baseline prevalence, follow-up incidence and cumulative lifetime-incidence of DSM-IV 
somatoform disorders and syndromes  
 
At baseline (first column of table I), 12.5% of the study sample reported that they had 
experienced at least one of the somatoform disorders or syndromes during their life. With 
2.6%, lifetime prevalence of any specific somatoform disorder was found to be rather rare. 
The most prevalent form of somatoform disorder was pain disorder (1.7%), while others such 
as conversion disorder and dissociative disorder NOS were quite rare (0.3% and 0.8%, 
respectively). No case met the criteria for somatization disorder and hypochondriasis. 
Somatoform syndromes as defined in our study were estimated with a lifetime prevalence of 
10.7 with USDS being the most prevalent subtype (9.0%). Women reported higher rates for 
pain disorder (3.2% vs. 0.3%; OR = 13.9;95%CI = 4.1–46.5) and for USDS (12.1% vs. 5.9%; 
OR = 2.3; 95% CI = 1.6–3.2).  
 
Among respondents who did not fulfill criteria for any of the assessed somatoform disorders 
and syndromes at baseline, the overall incidence rate for any of the covered diagnoses after 
the four year study period (T0–T2) was 25.7%, with a relatively higher incidence of 
somatoform syndromes (20.6%) when compared to full-blown somatoform disorders (7.3%). 
Among the latter, pain disorder was found to be the most common incident form of 
somatoform disorders (6.9%), while among somatoform syndromes, USDS was the condition 
with the highest incidence rate (20.3%). No incidence cases of somatization disorder and 
hypochondriasis were observed. Again, women reported higher incidence rates for pain 
disorder (10.7% vs. 3.2%; OR = 3.6; 95% CI = 2.4–5.4) and USDS (28.5% vs. 12.6%;OR = 
2.7; 95% CI = 2.2–3.5) when compared with men. Highest cumulative lifetime incidence rates 
at T2 were obtained for pain disorder (8.5%), SSI4,6 (2.6%) and USDS (27.5%), again with 
considerable gender differences.  
 
Changes in caseness of somatoform disorders from baseline to follow-up (T0–T2)  
 
Table II provides a cross-tabulation of the respondent’s diagnostic status at baseline and 
follow-up.  
 
The first column in table II indicates the probability of being well at follow-up. About half 
(51.7%) of any somatoform disorder or syndrome at baseline completely remitted during 
follow-up period. Specifically, reporting none of the assessed somatoform disorders and 
syndromes during the follow-up period, was highest for cases with USDS and dissociative 
disorder NOS at baseline (58.6% and 53.6%, respectively). For the other diagnoses, remission 
rates were considerably lower with 34.5% for pain disorder, 10.6% for conversion disorder, 
and 25.7% for SSI4,6. Considering first the same diagnostic outcome during the follow-up 
period, stability was highest for pain disorder and USDS. About 30% of cases with this 
diagnosis at baseline fulfilled criteria again at follow-up (pain disorder: 29.7%; USDS: 34.0%, 
respectively). As presented in table II, there were considerable proportions of transitions 
between the different somatoform conditions assessed in the study.  
 
This high stability within the overall diagnostic group of somatoform disorders/syndromes is 
also reflected by the conditional probability rates for the aggregated categories: almost 50% of 
all cases with any of the assessed somatoform disorders and syndromes reported any of these 
conditions again during follow-up, with a slightly higher stability rate for full-blown-disorders 
when compared to syndromes (60.8% vs. 46.6%).  
 
Because of the small sample sizes for most somatoform disorders, gender differences in 
stability were only evaluated for the aggregated diagnostic groups “any somatoform disorder 
or syndrome” as well as separately for “any somatoform disorder” and “any somatoform 
syndrome”. Compared to men, women reported a considerably higher stability for the overall 
category of “any somatoform disorder or syndrome” (53.9% vs. 34.3%; OR = 2.2; 95% CI = 
1.2–3.9) as well as for the subgroup of “any somatoform syndrome” (44.7% vs. 28.1%; OR = 
2.0; 95% CI = 1.0–3.8). The stability for the subgroup of “any somatoform disorder” even 
was higher for women compared to men, though this difference reached no significance 
(25.8% vs. 10.3%; OR = 3.0; 95% CI = 0.3–24.5).  
 
Factors associated with incidence and stability  
 
Due to the small sample sizes in the specific disorders under consideration, baseline factors 
were examined with regard to the outcome of the aggregated group of any somatoform 
disorder/syndrome (table III).  
 
Among the total group, being female, pre-existing substance use, affective and anxiety 
disorders as well as the experience of physical threat were significantly positively related to 
the incidence of somatoform disorders during the follow-up period. The experience of rape or 
sexual abuse was also found as predictor for the occurrence of new onsets of somatoform 
disorders/syndromes during follow-up, but this relationship was entirely due to females. We 
had no male who reported prior to baseline the experience of rape or sexual abuse and onset 
of somatoform disorders during follow-up. High social class as well as high educational level 
(Gymnasium) negatively predicted new onset of somatoform disorders during follow-up. 
Except for the experience of rape/sexual abuse mentioned above no differences in 
associations were found between males and females and between the younger and older 
cohort.  
 
Stability of somatoform disorders/syndromes was predicted by being female, prior history of 
any substance, affective or eating disorder as well as the experience of a prior serious 
accident. None of the demographic variables was associated with stability of somatoform 
disorders. All associations were comparable for males and females. For rape/sexual abuse, the 
interaction could not be computed, due to the fact that there was no male that experienced 
either rape or sexual abuse prior to baseline and persistence of somatoform disorders during 
follow-up. No differences in associations were found between the younger and the older 
cohort.  
 
Discussion  
 
The main aim of this paper was to estimate incidence and stability of several somatoform 
disorders and syndromes, and to investigate prospectively factors that are associated with their 
incidence and stability over a time period of about 4 years.  
 
Before discussing our findings, some limitations and caveats should be mentioned. (1) The 
EDSP is to our knowledge the first epidemiological study assessing a broader range of sub-
threshold and threshold somatoform conditions by using the redefined diagnostic definitions 
and criteria of DSM-IV. Thus, direct comparisons with other adolescent and adult community 
surveys based on other diagnostic criteria and instruments are cautioned. (2) The classification 
of symptoms into “clinically significant”, “fully explainable” and “not fully explainable” 
categories must be interpreted with some caution for different reasons. In our study we do not 
have “objective” data (e.g. laboratory evaluations) or a physical examination, which would 
perhaps provide more “hard” indicators to decide the physical basis of the symptoms 
classified as somatoform. The assessment of somatoform symptoms is based on the standard 
M-CIDI probe questions and relies on the respondent’s self-report. Symptoms are classified 
by health research interviewers or clinical psychologists, and—despite of the extensive 
training and supervision of the interviewers as well as the case-by-case reviews of the 
clinically experienced editors—we cannot totally be sure that none of the symptoms rated as 
“somatoform” had a medical explanation. (3) Although the M-CIDI diagnostic algorithms for 
threshold somatoform disorders have been tested for reliability and at least for some validity 
issues [25,36], the sub-threshold syndromes have not yet been explored psychometrically. (4) 
The diagnostic criteria for pain disorder were not entirely identical at baseline and follow-up. 
At baseline, subjects had to affirm that they were suffering at least 6 months due to the pain 
symptoms reported—that is, only “chronic” cases were counted. The 6-month criteria were 
not applied in the follow-up assessment what may have led to an overestimation of the 
incidence for pain disorder. (5) Although the respondents had two or three diagnostic 
evaluations, all information about symptoms relies on the subjects’ responses and is based on 
their recollections. Recall bias could have affected in some cases the accuracy of information 
regarding clinical significance (e.g. use of medication, consulting a doctor). Further, 
inconsistencies in the recall of symptoms could have further affected the reliability of the 
symptom reports [29]. Within the context of these limitations, the following findings are 
noteworthy.  
 
Somatoform disorders and syndromes are widespread among adolescents and young adults  
 
Already our baseline results reveal that somatoform disorders and syndromes as defined by 
the M-CIDI/DSM-IV criteria are quite prevalent in adolescents. Like other researchers 
[26,32,34,35] we found that the full-blown somatoform disorders are rather rare. However, 
somatoform syndromes beyond the diagnostic thresholds of the full-blown disorders (in our 
study defined according to the SSI4,6 as well as the USDS) seem to be considerably much 
more common. Taking the CIDIs convention to classify such sub-threshold syndromes by 
assigning the diagnosis whenever the person falls short of the mandatory criteria of the 
fullblown diagnosis, any of the somatoform syndromes assessed in the study was reported at 
baseline by about 10% of the respondents. In line with what other studies have reported 
[2,16,17,41], such sub-threshold somatoform syndromes are much more common in females 
than in males. Although one might speculate about the clinical meaning of these sub-threshold 
syndromes, our previous analyses [21] as well as other studies [7,14,18] could demonstrate 
increased rates of current and past disabilities as well as increased rates of health care 
utilization in individuals fulfilling diagnostic criteria of these syndromes. Thus, we believe 
that the assessed somatoform syndromes at this low diagnostic level are not merely trivial 
common complaints, but rather disabling conditions that deserve attention in research and 
clinical practice.  
 
The longitudinal design of our study allowed us to study for the first time the incidence of a 
range of somatoform disorders and syndromes in a community sample of adolescents and 
young adults. The only direct comparable study that provided incidence rates is the World 
Health Organization’s Psychological Problems in General Health Care project in the frame of 
which the incidence of somatization in terms of the abridged SSI4,6 was evaluated for a 12-
month interval [11]. Among primary care patients, the incidence of SSI4,6 was about 7%. For 
the SSI4,6, our study found a considerably lower incidence rate over a 4-year period with 
about 1% of new cases with SSI4,6. We assume that this difference in the incidence of SSI4,6 
might be explained by the older age range of the primary care sample as well as their clinical 
status. All our other incidence findings cannot be compared to previous findings—as such are 
not available. Nevertheless, we think that it is worthwhile to note that the overall incidence 
rate for pain disorder was about 7%, suggesting that even among young adults this seems to 
be a quite frequent clinical condition.  
 
Somatoform conditions are relatively stable and enduring, at least whenever the point of sub-
threshold diagnostic status is reached  
 
The natural course of somatoform disorders and syndromes in adolescents and young adults 
revealed a relatively unfavorable outcome pattern. In terms of diagnostic and syndrome 
stability over a period of about 4 years, our data suggest that for a substantial proportion of 
individuals, both threshold and subthreshold somatoform conditions are stable and enduring 
conditions. Thus, about 60% of all baseline threshold cases and 45% of the baseline sub-
threshold cases were still cases 4 years later at least on the subthreshold diagnostic status. A 
comparison of these stability rates with the stability rates that we have found for anxiety and 
depressive disorders [37] indicates that the overall persistence of somatoform conditions is as 
high as the persistence of depressive disorder (1-year stability rate 32% for sub-threshold 
cases and 51% for threshold cases) and even higher than the persistence of anxiety disorders 
(1-year stability rate 20% for subthreshold cases and 31% for threshold cases). The finding 
that 45% of all baseline sub-threshold and threshold cases were again classified as at least 
subthreshold cases at second follow-up is comparable to the observations from Gureje and 
Simon [11], who reported that, across diverse cultural settings, about half of the patients with 
SSI4,6 somatization in primary care facilities continued to meet the criteria after 1 year. 
However, our data also suggest that the specific syndrome pictures must not generally be 
chronic, there rather seems to be a remarkable degree of fluctuation or “mobility” between the 
different somatoform conditions. Thus, the results argue conceptually rather for an “overall” 
phenomenon of somatization with variations in the picture of the specific syndromes over 
time.  
 
Risk factors for incidence and persistence  
 
Our longitudinal analyses found that being female, pre-existing substance use, affective and 
anxiety disorders as well as the experience of physical threat increases the risk for 
somatoform conditions in adolescents and young adults. Among females, also the experience 
of rape or sexual abuse was found as predictor for the occurrence of new onsets of 
somatoform disorders/ syndromes. We found also that high social class as well as high 
educational level (Gymnasium) is negatively associated with new onset of somatoform 
disorders during follow-up. As, to our knowledge, no previous study examined risk factors for 
somatoform disorders prospectively by using a community sample there is no basis for 
comparing our results with a study that used a similar methodological approach. But, taking 
into account studies using clinical samples, some of the risk factor results obtained in our 
study are consistent with those found in previous research. Thus, Gureje and Simon [11] also 
found an association between preexisting depression and the onset of new somatization 
according to SSI4,6 over a 12-month follow-up period. Likewise, other previous research also 
suggests that specifically traumatic sexual experiences may increase the risk for later 
somatization in women [4,24,33].  
 
Persistence was related to being female, prior substance use, affective and eating disorders as 
well as the prior experience of a traumatic event, specifically a serious accident. Thus, both 
the persistence and incidence of somatoform conditions share some identical risk factors as 
they both relate to female gender, and the experience of substance use and affective disorders 
at baseline. Risk factors that are associated with onset but not with persistence of somatization 
include social class and education, anxiety disorders and specifically traumatic sexual events. 
It seems to be possible that, for example, anxiety disorders or the experience of traumatic 
sexual events sensitizes to the perception of bodily sensations, but, once somatic symptoms 
are manifested, their stability seems to depend on conditions other than anxiety.  
 
Conclusion  
 
Our results suggest that somatoform disorders/ syndromes are highly prevalent even among 
younger age groups. At least for a substantial proportion of individuals, the overall picture of 
somatization seems to be relatively stable, but with fluctuation in the symptom picture over 
time. Being female, the experience of substance use as well as anxiety disorders seem to 
constitute risk factors for the onset of new somatoform conditions as well as for a stable 
course over time. 
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